Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of ASP2151 on Midazolam PK in Healthy Men
NCT02403635Phase 1Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Apr 2015
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Amenamevir in herpes zoster (HZ), sponsored by Maruho Co., Ltd. Primary endpoints: Peak Plasma Concentration (Cmax) of Midazolam at Day 26, Time of Peak Concentration (Tmax) of Midazolam at Day 26 and 2 more. Started Apr 2015; status: completed.
02
Drugs
Amenamevir
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT02403635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02403635.